Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy

Supportive Care in Cancer

Volumn 18, Issue 11, 2010, Pages 1437-1444

  Gridelli, Cesare ^a   Haiderali, Amin M ^b   Russo, Mark W ^b   Blackburn, Linda M ^b   Lykopoulos, Konstantinos ^c  

^a S G MOSCATI HOSPITAL   (Italy)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Casopitant; Functional Living Index Emesis (FLIE) questionnaire; Highly emetogenic chemotherapy; Quality of life

Indexed keywords

CASOPITANT; CISPLATIN; DEXAMETHASONE; ONDANSETRON; PLACEBO; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FUNCTIONAL LIVING INDEX EMESIS QUESTIONNAIRE; HIGHLY EMETOGENIC CHEMOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG COMBINATION; MIDDLE AGED; NAUSEA; NEOPLASM; ORAL DRUG ADMINISTRATION; VOMITING;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; PIPERAZINES; PIPERIDINES; QUALITY OF LIFE; QUESTIONNAIRES; VOMITING; YOUNG ADULT;

EID: 79952117961     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-009-0766-4     Document Type: Article

References (23)

1. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. Support Care Cancer 13:219-227
2. Richardson JL, Marks G, Levine A (1988) The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 6:1746-1752
3. Schnell FM (2003) Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control. Oncologist 8:187-198
4. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497-503
5. Voliotis DL, Diehl V (1998) Clinical aspects and prognostic factors of nausea and vomiting after chemotherapy. In: DiCato MA (ed) Medical management of cancer treatment induced emesis. Martin Dunitz, Philadelphia, pp 45-54
6. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596-600
7. Dibble SL, Isreal J, Nussey B, Casey K, Luce J (2003) Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 30:E40-E47
8. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261-2268
9. Hickock JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytriptamine-3 antiemetics: A University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880-2886
10. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, Delprete S, Bachinski ME, Dirlam NL, Stack CB, Silberman SL (1999) Randomized phase II study of the neurokinin I receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis. J Clin Oncol 1791:338-343
11. Navari RM, Reinhart RR, Gralla RJ, Kris MG, Hesketh PJ, Kojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340:190-195
12. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides A, Eldridge K, Gertz BJ (2001) Comparison of L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-754, 030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835-842
13. Horgan KJ, Eldridge KN, Carides A, Van Belle S, Hesketh PJ (2001) Differential time course of cisplatin induced acute emesis with a 5HT3 antagonist or an NK1 antagonist: Rationale for combination therapy. Proc ASCO 20:383a Abstract
14. Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J (2009) Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: A randomized, double-blind, placebo-controlled trial. Lancet Oncol 10:549-558
15. Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Sp C, Grunberg SM (2003) Functional relevance of antiemetic control: Experience using the FLIE questionnaire in a randomized study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395-1401
16. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35-52
17. Bliss JM, Robertson B, Selby PJ (1992) The impact of nausea and vomiting upon quality of life measures. Br J Cancer Suppl 19: S14-S22
18. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
19. O'Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: Survey of five Canadian centres. CMAJ 149:296-302
20. Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179-185
21. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947
22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician-gls/ PDF/antiemesis.pdf. Accessed 1 August 2008
23. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy-and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28